Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
6,175,059
-
Share change
-
+2,433,642
-
Total reported value
-
$20,377,818
-
Put/Call ratio
-
152%
-
Price per share
-
$3.30
-
Number of holders
-
46
-
Value change
-
+$8,169,569
-
Number of buys
-
19
-
Number of sells
-
11
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q1 2023
As of 31 Mar 2023,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,175,059 shares.
The largest 10 holders included
AIGH Capital Management LLC, VANGUARD GROUP INC, BlackRock Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, Worth Venture Partners, LLC, ABNER HERRMAN & BROCK LLC, GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, SIMPLEX TRADING, LLC, and RAYMOND JAMES & ASSOCIATES.
This page lists
46
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.